Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | CTSC | P53634 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 8/20 | 0.56 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | BLK | P51451 | 1/20 | 0.56 |
| ▸ | BMX | P51813 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392903 | 0.86 | TGM2 (0.59) | TGM2EGFRJAK3JAK2BLK | |
| SCHEMBL10361955 | 0.81 | JAK3 (0.61) | TGM2EGFRJAK3JAK2BLK | |
| SCHEMBL8151744 | 0.78 | MTNR1B (0.74) | TGM2 | |
| SCHEMBL23243709 | 0.77 | CTSC (0.78) | CTSCEGFRJAK3JAK2BLK | |
| SCHEMBL9017578 | 0.76 | TGM2 (1.00) | TGM2EGFR | |
| SCHEMBL21392902 | 0.75 | TGM2 (0.71) | TGM2EGFRBLKBTK | |
| SCHEMBL14341775 | 0.75 | TGM2 (0.86) | TGM2EGFR | |
| SCHEMBL10127822 | 0.75 | CTSC (0.69) | CTSCEGFRJAK3JAK2BLK | |
| SCHEMBL23421844 | 0.75 | BTK (0.68) | CTSCEGFRJAK3JAK2BLK | |
| SCHEMBL10127782 | 0.75 | MAP3K7 (0.75) | CTSCEGFRJAK3JAK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | TGM2 2225/4885CTSC 496/4885EGFR 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.